{"title":"关于通过分泌胱氨酸酶的基因工程细胞交叉矫正胱氨酸病的研究","authors":"V. Graceffa","doi":"10.2174/0122115501271925231130074832","DOIUrl":null,"url":null,"abstract":"\n\nCystinosis is a rare inherited lysosomal storage disease (LSD), caused by\na mutation in the Cystinosin Lysosomal Cystine Transporter (CTNS). Novel therapies and strategies are needed to improve patients' clinical conditions and quality of life.\n\n\n\nThis study assessed whether CTNS can be secreted, and investigated a\nmethod to enhance its secretion, by adding a secretion signal to the N-terminus. Human Embryonic Kidney (HEK) 293 cells were transfected with the resulting construct. The amount of protein\nsecreted was then measured. Uptake by monolayer cultures of cystinotic cells and enzyme activity were also assessed.\n\n\n\nThe recombinant protein could effectively be secreted, and the secretion signal slightly\nfurther increased its secretion. The secreted recombinant protein was taken up by cystinotic cells,\nand, after internalization, still retained its biological activity.\n\n\n\nOptimization of the proposed method to increase the secretion of CTNS would provide new insights into the production of recombinant proteins for medical and industrial use. Further identification and screening of alternative signalling peptides and cell types can maximise the\nsecretion and production of recombinant CNTS, to be used as a therapeutic agent in human\nhealthcare.\n","PeriodicalId":10850,"journal":{"name":"Current Biotechnology","volume":"22 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigation on Cross-correction of Cystinosis through Genetically\\nEngineered Cells Secreting Cystinosin\",\"authors\":\"V. Graceffa\",\"doi\":\"10.2174/0122115501271925231130074832\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nCystinosis is a rare inherited lysosomal storage disease (LSD), caused by\\na mutation in the Cystinosin Lysosomal Cystine Transporter (CTNS). Novel therapies and strategies are needed to improve patients' clinical conditions and quality of life.\\n\\n\\n\\nThis study assessed whether CTNS can be secreted, and investigated a\\nmethod to enhance its secretion, by adding a secretion signal to the N-terminus. Human Embryonic Kidney (HEK) 293 cells were transfected with the resulting construct. The amount of protein\\nsecreted was then measured. Uptake by monolayer cultures of cystinotic cells and enzyme activity were also assessed.\\n\\n\\n\\nThe recombinant protein could effectively be secreted, and the secretion signal slightly\\nfurther increased its secretion. The secreted recombinant protein was taken up by cystinotic cells,\\nand, after internalization, still retained its biological activity.\\n\\n\\n\\nOptimization of the proposed method to increase the secretion of CTNS would provide new insights into the production of recombinant proteins for medical and industrial use. Further identification and screening of alternative signalling peptides and cell types can maximise the\\nsecretion and production of recombinant CNTS, to be used as a therapeutic agent in human\\nhealthcare.\\n\",\"PeriodicalId\":10850,\"journal\":{\"name\":\"Current Biotechnology\",\"volume\":\"22 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Biotechnology\",\"FirstCategoryId\":\"1087\",\"ListUrlMain\":\"https://doi.org/10.2174/0122115501271925231130074832\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Biotechnology","FirstCategoryId":"1087","ListUrlMain":"https://doi.org/10.2174/0122115501271925231130074832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Investigation on Cross-correction of Cystinosis through Genetically
Engineered Cells Secreting Cystinosin
Cystinosis is a rare inherited lysosomal storage disease (LSD), caused by
a mutation in the Cystinosin Lysosomal Cystine Transporter (CTNS). Novel therapies and strategies are needed to improve patients' clinical conditions and quality of life.
This study assessed whether CTNS can be secreted, and investigated a
method to enhance its secretion, by adding a secretion signal to the N-terminus. Human Embryonic Kidney (HEK) 293 cells were transfected with the resulting construct. The amount of protein
secreted was then measured. Uptake by monolayer cultures of cystinotic cells and enzyme activity were also assessed.
The recombinant protein could effectively be secreted, and the secretion signal slightly
further increased its secretion. The secreted recombinant protein was taken up by cystinotic cells,
and, after internalization, still retained its biological activity.
Optimization of the proposed method to increase the secretion of CTNS would provide new insights into the production of recombinant proteins for medical and industrial use. Further identification and screening of alternative signalling peptides and cell types can maximise the
secretion and production of recombinant CNTS, to be used as a therapeutic agent in human
healthcare.